{
    "organizations": [],
    "uuid": "48628716ab2cba3963c880fa6cca757517e434a1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ipsen-biopharmaceuticals-canada-sa/brief-ipsen-biopharmaceuticals-canada-says-health-canada-approved-somatuline-autogel-for-treatment-of-carcinoid-syndrome-idUSFWN1Q30YU",
    "ord_in_thread": 0,
    "title": "Ipsen Biopharmaceuticals Canada Says Health Canada Approved Somatuline Autogel For Treatment Of Carcinoid Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Ipsen Sa:\n* IPSEN BIOPHARMACEUTICALS CANADA SAYS HEALTH CANADA APPROVES SOMATULINE AUTOGEL (LANREOTIDE INJECTION) 120 MG FOR TREATMENT OF CARCINOID SYNDROME Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T20:43:00.000+02:00",
    "crawled": "2018-02-14T12:16:30.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "ipsen",
        "sa",
        "ipsen",
        "biopharmaceuticals",
        "canada",
        "say",
        "health",
        "canada",
        "approves",
        "somatuline",
        "autogel",
        "lanreotide",
        "injection",
        "mg",
        "treatment",
        "carcinoid",
        "syndrome",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}